Point72 Asset Management
PSTX

Point72 Asset Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Point72 Asset Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-335,000
Closed -$1.13M – 2705
2023
Q4 		$1.13M Buy
335,000
+235,000
+235% +$605K ﹤0.01% 1370
2023
Q3 		$238K Buy
+100,000
New +$210K ﹤0.01% 1724
2023
Q2 		– Sell
-5,264
Closed -$16.2K – 2900
2023
Q1 		$16.2K Buy
+5,264
New +$31.6K ﹤0.01% 1995

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Point72 Asset Management's PSTX Position: Q1 2024 in Review

Point72 Asset Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2024, closing a stake of 335,000 shares — an estimated $1.13M sold.

Point72 Asset Management first reported a position in PSTX in Q1 2023 and held it in 3 quarters. The position peaked at $1.13M in Q4 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q1 2024.

  • Point72 Asset Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 335,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.13M.
  • Point72 Asset Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • Point72 Asset Management's Poseida Therapeutics, Inc. Common Stock position peaked at $1.13M in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.